Literature DB >> 33655969

Tacrolimus-induced epilepsy with primary membranous nephropathy: A case report.

Yan Yang1, Lei Zhang2, Ying Mo2, Rong Ren2, Fengmei Wang1.   

Abstract

RATIONALE: Tacrolimus-associated neurologic disorders can be found in some cases, mainly in organ transplantation patients. However, epilepsy induced by tacrolimus in primary membranous nephropathy (PMN) patient is scare. PATIENT CONCERNS: A 63-year-old man experienced 1-year history of foamy urine, and edema of lower extremity. DIAGNOSIS: The patient had proteinuria, hypoalbuminemia, which indicated nephrotic syndrome. Further, we performed renal biopsy for this patient. Combined with the renal biopsy result, the diagnosis of primary membranous nephropathy was established. INTERVENTION: At first, irbesartan was administrated for 6 months. However, the proteinuria had no obvious improvement. Tacrolimus was administrated afterwards. OUTCOMES: Twenty-two days after tacrolimus treatment, epilepsy occurred. Sodium valproate and carbamazepine were successively given to control epilepsy. However, the epileptic symptoms were not effectively controlled. During the treatment, the concentration of tacrolimus fluctuated greatly. At last, levetiracetam was given to maintain the curative effect. Fortunately, the patient did not suffer from epilepsy again. The concentration of temporary tacrolimus was stable, whereas proteinuria gradually decreased. LESSONS: Tacrolimus-induced epilepsy should be considered in patients exhibiting acute neurological symptoms. Early diagnosis and effective treatment play a vital role for favorable prognosis.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33655969      PMCID: PMC7939194          DOI: 10.1097/MD.0000000000024989

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  20 in total

1.  Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.

Authors:  Nicola M Tomas; Laurence H Beck; Catherine Meyer-Schwesinger; Barbara Seitz-Polski; Hong Ma; Gunther Zahner; Guillaume Dolla; Elion Hoxha; Udo Helmchen; Anne-Sophie Dabert-Gay; Delphine Debayle; Michael Merchant; Jon Klein; David J Salant; Rolf A K Stahl; Gérard Lambeau
Journal:  N Engl J Med       Date:  2014-11-13       Impact factor: 91.245

2.  Severe neurological events following liver transplantation.

Authors:  Fuat Hakan Saner; Georgious C Sotiropoulos; Yanli Gu; Andreas Paul; Arnold Radtke; Julia Gensicke; Ilker Kavuk; Massimo Malagó; Christoph E Broelsch
Journal:  Arch Med Res       Date:  2006-11-03       Impact factor: 2.235

Review 3.  Carbamazepine-related antiepileptic drugs for the treatment of epilepsy - a comparative review.

Authors:  Jaime Gierbolini; Melissa Giarratano; Selim R Benbadis
Journal:  Expert Opin Pharmacother       Date:  2016       Impact factor: 3.889

4.  Central nervous system complications in liver transplant recipients--incidence, timing, and long-term follow-up.

Authors:  D J Bronster; S Emre; P Boccagni; P A Sheiner; M E Schwartz; C M Miller
Journal:  Clin Transplant       Date:  2000-02       Impact factor: 2.863

5.  Reversible posterior encephalopathy syndrome in children with nephrotic syndrome.

Authors:  Juan Zhou; Helin Zheng; Xuefei Zhong; Daoqi Wu; Mo Wang; Xuemei Tang; Qiu Li
Journal:  Nephrology (Carlton)       Date:  2015-11       Impact factor: 2.506

6.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.

Authors:  Laurence H Beck; Ramon G B Bonegio; Gérard Lambeau; David M Beck; David W Powell; Timothy D Cummins; Jon B Klein; David J Salant
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

7.  Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome.

Authors:  Kim Loeffler; Manjula Gowrishankar; Verna Yiu
Journal:  Pediatr Nephrol       Date:  2004-02-03       Impact factor: 3.714

8.  Posterior reversible leukoencephalopathy syndrome (PRES) after kidney transplantation: a case report.

Authors:  Carla Beatriz Davi; Bruna Pinheiro de Moraes; Bruno Fontes Lichtenfels; João Batista Saldanha de Castro Filho; Marcelle Maria Portal; Rosangela Munhoz Montenegro; Roberto Ceratti Manfro
Journal:  J Bras Nefrol       Date:  2018-04-19

Review 9.  Recent Topics on The Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities.

Authors:  Wei Zhang; Nobuaki Egashira; Satohiro Masuda
Journal:  Int J Mol Sci       Date:  2019-06-29       Impact factor: 5.923

10.  Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial.

Authors:  Andrew Howman; Tracey L Chapman; Maria M Langdon; Caroline Ferguson; Dwomoa Adu; John Feehally; Gillian J Gaskin; David R W Jayne; Donal O'Donoghue; Michael Boulton-Jones; Peter W Mathieson
Journal:  Lancet       Date:  2013-01-09       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.